Abstract: A method and vaccine for treatment of pythiosis in humans and animals is described. In particular a vaccine comprising a mixture of extracellular and intracellular proteins is described. The vaccine enables cures of chronic pythiosis in some patients.
Type:
Grant
Filed:
July 17, 1997
Date of Patent:
September 7, 1999
Assignee:
Board of Trustees operating Michigan State University
Abstract: The invention relates to novet Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.
Type:
Grant
Filed:
May 16, 1995
Date of Patent:
August 24, 1999
Assignees:
SmithKline Beecham Biologicals, Max-Planck-Gesellschaft zur Forderung der Wissenschafter e.V., Duetsches Krebsforschungszentrum Stiftung des offentlichen Rechts
Inventors:
Yves Lobet, Markus Simon, Ulrich Schaible, Reinhard Wallich, Michael Kramer
Abstract: A method of cultivating bacteria having genes in plasmids which code for surface or membrane bound antigens or other proteins and which are expressed in a temperature regulated manner for the production of desired bacterial products, is disclosed. The bacteria are first cultivated in a culture medium to an inoculum under such temperature conditions that the bacteria retain their plasmids and no expression occurs, e.g. 20.degree. C., and then in a culture medium under such temperature conditions that expression occurs and before the bacteria lose their plasmids they are harvested, and the desired product is isolated.
Type:
Grant
Filed:
April 21, 1997
Date of Patent:
August 10, 1999
Assignee:
SBL Vaccin AB
Inventors:
Per Askelof, Nils Carlin, Bo Nilsson, Agneta Paulsson
Abstract: The invention provides ribA polypeptides and polynucleotides encoding ribA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ribA polypeptides to screen for antibacterial compounds.
Inventors:
Michael Terence Black, Jason Craig Fedon, John Edward Hodgson, David Justin Charles Knowles, Michael Arthur Lonetto, Anna Lisa Kosmatka, Richard Oakley Nicholas, Leslie Marie Palmer, Lisa Kathleen Shilling, Robert King Stodola, Richard Lloyd Warren
Abstract: A novel hybrid protein is provided which comprises a portion of the CS protein of P. falciparum and the surface antigen of Hepatitis B virus. The use of this protein for vaccination purposes is disclosed.
Abstract: A method of reversing or preventing immunosuppression or antigenic interference associated with combination vaccines in mammals, is disclosed. Cytokines, or cytokine inducer, are administered in conjunction with the combination vaccine. The cytokine or cytokine inducer can be administered concurrently with or subsequently to the vaccine, and can be recombinantly produced or isolated from cell culture.
Type:
Grant
Filed:
May 31, 1995
Date of Patent:
July 27, 1999
Assignee:
American Cyanamid Company
Inventors:
Michael Joseph Daley, Phillip Wayne Hayes
Abstract: Described is a vaccine against Actinobacillus pleuropneumoniae (APP) comprising genetically defined biochemically attenuated mutant of APP that requires riboflavin and is attenuated in vivo.
Type:
Grant
Filed:
October 28, 1996
Date of Patent:
July 20, 1999
Assignee:
Michigan State University
Inventors:
Troy E. Fuller, Martha H. Mulks, Bradley Thacker
Abstract: The present invention encompasses methods for reducing or inhibiting growth factor in cancer cells and tissues. More particularly immunogenic growth factor-containing compositions are administered to a human or animal with a cancer or tumor. The immunogenic compositions elicit the production of antibodies specific for growth factor which reduce the level of circulating growth factor, thus reducing or eliminating the proliferation of cancer. The present invention encompasses growth factor-containing liposomes and vesicles having portions of growth factor externally presented on their surfaces. The present invention also includes antibodies specific for growth factor. Thus, according to the present invention, growth factor levels are reduced either by active immunization of an individual using immunogenic growth factor-containing compositions or by passive immunization via administering to the individual an antibody or a group of antibodies specific for growth factor.
Abstract: Immunological adjuvant containing GMDP (N-acetyl-glucos-aminyl-N-acetylmuramyl-L-alanyl-D-isoglutamine) and a colloidal, ultrafiltrable solution of solid, biodegradable lipids suitable as an additive in veterinary and human vaccines.
Abstract: Methods are disclosed for administering Peptide YY (PYY) receptor agonists to birds in ovo to promote altricial development of the intestinal tract of neonatal birds. Enhanced altricial development of the small intestine in hatchling birds results in an increased absorption of nutrients from the small intestine without a concomitant increase in energy expenditure, thereby resulting in an improved efficiency of nutrient utilization, enhanced rate of post-hatch growth, and reduced post-hatch mortality rate in PYY-treated birds.
Type:
Grant
Filed:
June 13, 1997
Date of Patent:
June 29, 1999
Assignees:
North Carolina State University, Medical University of South Carolina
Inventors:
Warren J. Croom, Jr., Ian L. Taylor, Barbara A. Coles
Abstract: The present invention relates to contraceptive vaccines based on cloned zona pellucida genes and the strategy of alloimmunization with zona pellucida polypeptides. In particular, the present invention relates to a contraceptive vaccine for use in a mammalian female comprising a polypeptide which displays at least one epitope for binding of an antibody that inhibits fertilization of an oocyte by a sperm. This epitope is from a zona pellucida procein of the species in which the said vaccine is used. This invention relates, more particularly, to such vaccines wherein the zona pellucida protein is either the ZP3 or the ZP2 or the ZP1 protein or the mouse or homologues of these proteins in some other mammalian species. Further, this invention comprehends vaccines comprising a synthetic peptide that displays an epitope for such an antibody that inhibits fertilization. In addition, this invention relates to cloned DNA segments variously encoding the mouse ZP3 or ZP2 proteins or the human ZP3 or ZP2 protein.
Type:
Grant
Filed:
May 23, 1997
Date of Patent:
June 29, 1999
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: Diphtheria toxin polypeptides comprising a mutant R binding domain exhibit reduced target cell binding and may be used as vaccines to immunize a mammal against infection by Corynebacterium diphtheria.
Type:
Grant
Filed:
June 8, 1994
Date of Patent:
June 29, 1999
Assignees:
President and Fellows of Harvard College, The Regents of the University of California
Inventors:
R. John Collier, Wei Hai Shen, David Eisenberg, Seunghyon Choe
Abstract: A consensus poptide of 36 amino acids has been designed which acts as an immunogen raising antibodies against the proteins of all members of the E. coli family CS4-CFA/1. While the N-terminus of members of this family of organisms shows a high degree of identity, the remainder of the sequence of the proteins shows much less homology across the strains. The region of the protein represented in the subunit encompasses known linear B- and T-cell epitopes of CFA/I. The consensus peptide has a high level of homology to strains bearing six different colonization factors.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
June 22, 1999
Assignee:
The United States of America as represented by the Secretary of the Army
Abstract: Compounds and methods are provided for diagnosing Leishmania infection. Disclosed compounds include polypeptides that contain at least an epitope of the Leishmania chagasi acidic ribosomal antigen LcP0, or a variant thereof. Such compounds are useful in a variety of immunoassays for detecting Leishmania infection and for identifying individuals with asymptomatic infections that are likely to progress to acute visceral leishmaniasis. The polypeptide compounds are further useful in vaccines and pharmaceutical compositions for preventing leishmaniasis.
Abstract: An improved method and vaccine is provided for the immunization of swine against infectious diseases caused by RTX toxin-secreting bacteria (e.g., porcine pleuropneumonia) which comprises administering to swine an effective amount of a live, immunizing, RTX toxin-secreting organism which induces in the swine a sufficiently high RTX toxin-neutralizing antibody titer to at least prevent clinical symptoms of the disease in the swine. For example, an intranasally administered, live, low virulence strain of A. suis (EM1) confers immunity upon swine against challenge with a virulent, disease-causing strain of A. pleuropneunmoniae.
Type:
Grant
Filed:
October 12, 1995
Date of Patent:
June 1, 1999
Assignee:
Kansas State University Research Foundation
Abstract: The present invention relates to a live attenuated strain of the bacterium Streptococcus equi, a pathogen causing strangles in horses. The invention also relates to a vaccine against strangles, methods for the preparation of such a vaccine and to the use of the strain for the preparation of such a vaccine.
Type:
Grant
Filed:
January 27, 1997
Date of Patent:
April 20, 1999
Assignee:
Provost Fellows & Scholars of the College of the Univ. of the Holy Undivided Trinity of Queen Elisabeth
Inventors:
Orla Mary Hartford, Timothy James Foster, Antonius Arnoldus Christiaan Jacobs
Abstract: The invention provides novel uses of EGF and vaccine compositions comprising EGF. In particular, autologous EGF, or a fragment or a derivative thereof, is used as an active immunization against the proliferation of EGF-dependent tumors, or other EGF-dependent diseases. Autologous EGF is preferably coupled to a carrier protein, such as tetanus toxoid or Cholera toxin B chain. The vaccine compositions according to the invention will usually comprise an adjuvant such as aluminum hydroxide.
Abstract: The invention provides tarF polypeptides and DNA (RNA) encoding tarF polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tarF polypeptides to screen for antibacterial compounds.
Type:
Grant
Filed:
July 18, 1997
Date of Patent:
March 30, 1999
Assignee:
SmithKline Beecham Corporation
Inventors:
Alison Frances Chalker, Stephanie Van Horn, Andrew Peter Fosberry, Michael Ovari
Abstract: Compositions of the current invention are directed toward inhibiting the growth of microorganisms, particularly fungi. The compositions consist of chemically-synthesized antibiotics comprising certain amino acids. Methods of identifying particular antibiotic compositions from libraries of such compositions are disclosed. In addition, methods for preventing microbial growth in plants and animals are disclosed. Methods and compositions are also disclosed which relate to synergistic combinations of inhibitory peptides with other antimicrobial compounds.
Abstract: The invention provides Saliva Binding Protein polypeptides and DNA (RNA) encoding Saliva Binding Protein polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Saliva Binding Protein polypeptides to screen for antibacterial compounds.